The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, continues to make good progress in 2025 with key regulatory and ...

Late-stage candidates include DNAtrix' tasadenoturev for recurrent glioblastoma, GeneLux' Olvi-Vec for ovarian cancer, Merck/Viralytics' Cavatek for various solid tumours, and Oncolytics Biotech's ...

After hours: 21 March at 7:19:54 pm GMT-4 Loading Chart for ONCY ...

A company presentation will take place during the conference’s Innovation track on Friday, March 28th at 9:00am. NeauxCancer conference’s Innovation track spotlights the most promising emerging ...

Bristol-Myers Squibb has also done a big oncolytic virus deal, acquiring rights late last year to an “armed virus” targeting cancer from the UK biotech, PsiOxus Therapeutics, worth almost $900 ...

Net research and development expenses for the device division increased in 2024 to CAD175,000 from CAD44,000 in 2023, a 400% increase. The increase is attributed to development of a new software ...

U.S. Food and Drug Administration states that data from the ongoing OnPrime/GOG-3076 Phase 3 registrational trial could potentially support ...

So, here we are, launching our fourth edition of Fierce Biotech's layoff tracker. As always, if you know of a layoff occurring at a biotech, please reach out to the Fierce Biotech editorial team ...